Multi-modality Prostate Cancer Image Guided Interventions

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-12

Study Completion Date

2023-06-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a non-randomized, prospective trial of men who are scheduled for radical prostatectomy for treatment of prostate cancer, or repeat biopsy for localized prostate cancer as standard of care and who will undergo a series of pre-operative multi-modality imaging studies. Post intervention, hybrid imaging maps (HIM) will be generated and the predictions of the HIM (3D location, volume and grade of cancer) will be correlated with actual pathology results to gauge the performance of the HIM in both radical prostatectomy and biopsy settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy

NCT02131649

Prostate Cancer

COMPLETED NA

Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy

NCT04053842

Prostate Cancer Prostate Adenocarcinoma Prostate Neoplasm

ACTIVE_NOT_RECRUITING PHASE2

PSMA-PET Registry for Recurrent Prostate Cancer

NCT03718260

Recurrent Prostate Cancer

RECRUITING NA

A Study of Participants With Advanced Prostate Cancer in Canada

NCT03501173

Prostatic Neoplasms

COMPLETED

Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer

NCT01804231

Prostate Cancer

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was built on our first study (IGPC-1, REB number 15551) which acquired multi-modality imaging in 36 patients undergoing radical prostatectomy. We successfully demonstrated the ability to accurately co-register pre-operative multi-modality images (MRI: T1, T2, Diffusion Weighed (DW), Dynamic Contrast enhanced (DCE); Dynamic Contrast Enhanced CT, 3D Ultrasound with post-operative whole mount pathology specimens. We have developed a platform for the segmentation of prostate cancer on the whole mount pathology specimens and are in the process of analyzing the data to develop a hybrid imaging map (HIM) of prostate cancer distribution (location and grade) based on the correlation of the pre-operative imaging signals and the post-operative pathology (citation provided below). The HIM will need subsequent validation in a separate cohort of radical prostatectomy patients and evaluated as to its ability to be incorporated as a targeting tool for prostate interventions such as prostate biopsy and this is the purpose of this follow-up study.

On the IGPC-2 study, pre-operative imaging panels were successfully obtained in 24 patients accrued to cohort 1. The protocol was then amended to include \[18-F\]-DCFPyl instead of \[18F\]-FCH. \[18-F\]-DCFPyl was a newer PET probe that may possess superior performance because it is directed against prostate specific membrane antigen (PSMA), a protein commonly expressed on prostate cancer cells. Imaging-pathology correlations in the first 6 patients imaged with \[18-F\]-DCFPyl were compared to the correlations obtained with \[18F\]-FCH imaging in the first 24 patients.

IGPC-2 Cohort 1 (Radical Prostatectomy) was expanded to provide an additional 20 men imaged with \[18-F\]-DCFPyl as part of the imaging panel. The goal was to acquire 24 complete imaging datasets with \[18-F\]-DCFPyl as the PET imaging agent to enable us to draw comparisons with the 24 \[18F\]-FCH imaging data sets acquired.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Imaging Panel

Patients who provided written informed consent and found to be eligible for study were asked to complete Positron Emission Tomography (PET) + Dynamic CT imaging, PET/MRI (with endorectal coil) and 3D-Transrectal ultrasound prior to standard of care radical prostatectomy.

Group Type EXPERIMENTAL

Imaging Panel

Intervention Type OTHER

Initial Protocol (REB approval date 08-Sept-2011)

Pre-operative Imaging Panel

* \[18F\]-FCH PET + Dynamic CT
* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)
* 3D-Transrectal ultrasound
* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)
* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)

Protocol Amendment #3, REB approval date 20-Oct-2015:

Pre-operative Imaging Panel

* \[18-F\]-DCFPyL PET+Dynamic CT
* PET/MRI with endorectal coil
* 3D-Transrectal Ultrasound
* Optional Sodium (23Na) MRI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Imaging Panel

Initial Protocol (REB approval date 08-Sept-2011)

Pre-operative Imaging Panel

* \[18F\]-FCH PET + Dynamic CT
* MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)
* 3D-Transrectal ultrasound
* Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)
* Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)

Protocol Amendment #3, REB approval date 20-Oct-2015:

Pre-operative Imaging Panel

* \[18-F\]-DCFPyL PET+Dynamic CT
* PET/MRI with endorectal coil
* 3D-Transrectal Ultrasound
* Optional Sodium (23Na) MRI

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of informed consent for this study
* Male, aged 18 years or older
* Pathologically confirmed prostate cancer on previous biopsy
* Suitable for and consenting to Radical Prostatectomy for treatment, or repeat biopsy as standard of care

Exclusion Criteria

* Prior therapy for prostate cancer (including hormone therapy), with the exception of radiation therapy for Cohort 2 only
* Use of 5-alpha reductase inhibitors, i.e. finasteride (Proscar) or dutasteride (Avodart) within 6 months of study start. Patients undergoing a 6-month washout period prior to study start will be eligible.
* Inability to comply with the pre-operative imaging panel
* Patients scheduled for radical prostatectomy with prostate size exceeding dimensions for whole mount pathology slides
* Allergy to contrast agents to be used as part of the imaging panel
* Sickle cell disease or other anemias
* Insufficient renal function (eGFR \< 60 mL/min/1.73 m2)
* Residual bladder volume \> 150 cc (determined by post-void ultrasound)
* Hip prosthesis, vascular grafting that is MRI incompatible or sources of artifact within the pelvis
* Contraindication to MRI

* pacemaker or other electronic implants
* known metal in the orbit
* cerebral aneurysm clips

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No